Access Program Information
Congenital hyperinsulinism is a rare condition that can cause life-threatening hypoglycemia.
Current treatment for congenital hyperinsulinism is often suboptimal, and such individuals
may respond to a new somatostatin analog, pasireotide. This is a compassionate use study of
the effects of pasireotide on individuals with suboptimally treated congenital
hyperinsulinism.